Clinical trials · Los Angeles, CA
HER2-negative Breast Cancer clinical trials in Los Angeles
We’re tracking 29 recruiting her2-negative breast cancer studies with a site in or near Los Angeles — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Los Angeles
- NCT06625775RecruitingPhase 1
Study of BBO-10203 for advanced solid tumors
This trial tests a new drug called BBO-10203, alone or combined with other cancer treatments, for people with certain advanced breast, colorectal, or lung cancers. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06058377RecruitingPhase 3
Adding immunotherapy to chemo for stage II-III breast cancer
This trial tests whether adding the immunotherapy drug durvalumab to standard chemotherapy works better than chemo alone for people with hormone receptor positive, HER2 negative breast cancer that is stage II or III and has a high-risk genetic score (MammaPrint High Risk 2).
Los Angeles, CaliforniaAges 18 years+ - NCT05304962RecruitingPhase 1
Test drug RGT-419B for advanced ER+ HER2- breast cancer
This Phase 1 study tests a new drug (RGT-419B), given alone or with hormone (endocrine) therapy, in people with advanced ER-positive, HER2-negative breast cancer that has progressed after standard treatments. It looks mainly at safety and early signs of how well the treatment may work.
Los Angeles, CaliforniaAges 18 years+ - NCT07062965RecruitingPhase 3
PF-07248144 with fulvestrant for HR+ HER2- advanced breast cancer
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
Los Angeles, CaliforniaAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
Los Angeles, CaliforniaAges 12 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study of rinatabart sesutecan for advanced solid tumors
This trial tests an investigational drug called rinatabart sesutecan (also known as Rina-S) for people with advanced solid tumors, including ovarian, endometrial, lung, breast, and other cancers. The drug is designed to target and kill cancer cells, and the study aims to see if it is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Los Angeles, CaliforniaAges 18 years+ - NCT05564377RecruitingPhase 2
Find targeted cancer treatments using genetic testing
This study matches people with advanced solid tumors to targeted treatment plans based on genetic testing. It also requires tumor sample testing to help doctors choose the most promising therapy for your specific tumor changes.
Los Angeles, CaliforniaAges Any age - NCT05879926RecruitingPhase 3
Testing chemo after hormone therapy in premenopausal early breast cancer
This Phase 3 trial checks whether adding chemotherapy after standard hormone-blocking treatment works better for some premenopausal women with early-stage, ER-positive, HER2-negative breast cancer. It targets patients with limited lymph node spread and a lower-to-intermediate tumor “recurrence” risk score.
Los Angeles, CaliforniaAges 18–60 - NCT05646862RecruitingPhase 3
Comparing two treatments for advanced breast cancer with a PIK3CA mutation
This trial tests whether a new drug combo (inavolisib plus fulvestrant) works better than an existing one (alpelisib plus fulvestrant) for people with a specific type of advanced breast cancer that has a PIK3CA mutation. It aims to find a treatment that may help control the cancer longer.
Los Angeles, CaliforniaAges 18 years+ - NCT07054190RecruitingPhase 2
Testing inavolisib for early-stage PIK3CA-mutated breast cancer
This study tests a new drug called inavolisib for people with early-stage breast cancer that has a specific genetic change (PIK3CA mutation). The goal is to see if adding this drug to standard hormone therapy is safe and effective before surgery.
Los Angeles, CaliforniaAges 18 years+ - NCT06757634RecruitingPhase 3
A study of gedatolisib for first-line advanced breast cancer
This trial tests a new targeted therapy called gedatolisib for people with HR-positive, HER2-negative advanced breast cancer who have not yet received treatment for metastatic disease. It aims to see if adding this drug to standard hormone therapy can help control the cancer longer.
Los Angeles, CaliforniaAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Los Angeles, CaliforniaAges 18 years+ - NCT06790693RecruitingPhase 3
Inavolisib plus hormone therapy for advanced breast cancer
This trial tests a new targeted therapy, inavolisib, combined with standard hormone therapy and a CDK4/6 inhibitor for people with a specific genetic mutation (PIK3CA) in their hormone receptor-positive, HER2-negative advanced breast cancer that has not been treated before. It compares this combination to a placebo plus the same standard treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT01042379RecruitingPhase 2
Adaptive drug trial for newly diagnosed breast cancer
This study tests personalized, changing treatment plans (given before surgery) to find better options for your specific breast tumor. You may be asked for extra breast-tissue testing to help match you with the most suitable study drug(s).
Los Angeles, CaliforniaAges 18 years+ - NCT06764940RecruitingPhase 2
Utidelone and capecitabine for HER2-negative breast cancer with brain metastases
This trial tests if the combination of Utidelone and capecitabine can shrink brain metastases in people with HER2-negative breast cancer. It is designed for those whose cancer has spread to the brain and who have not had many prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT04852887RecruitingPhase 3
Testing shorter breast radiation after low-risk hormone breast cancer
This Phase 3 trial studies whether “less intense” radiation can work as well as standard radiation for certain early-stage hormone receptor–positive, HER2-negative breast cancers that have a low Oncotype DX score. It may help reduce treatment burden while keeping cancer control strong.
Los Angeles, CaliforniaAges 50–70 - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Los Angeles, CaliforniaAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Los Angeles, CaliforniaAges 18 years+ - NCT06369285RecruitingPhase 2
Alisertib and hormone therapy for advanced breast cancer
This trial tests a new drug, alisertib, combined with hormone therapy for people with HR-positive, HER2-negative breast cancer that has spread or come back and is no longer curable. It may be an option if you've already tried at least two hormone therapies and a CDK4/6 inhibitor.
Los Angeles, CaliforniaAges 18 years+ - NCT06380751RecruitingPhase 3
New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
Los Angeles, CaliforniaAges 18 years+ - NCT04305834RecruitingPhase 2
Abemaciclib plus hormone pills for metastatic breast cancer in older adults
This Phase 2 study tests whether abemaciclib combined with standard hormone (endocrine) therapy can better control metastatic breast cancer in people age 70 and older. It may help if your cancer has already grown despite prior hormone therapy and/or other cancer medicines.
South Pasadena, CaliforniaAges 70 years+ - NCT07391774RecruitingPhase 3
Hormone therapy with or without chemo for early breast cancer
This trial tests whether skipping chemotherapy and using only hormone therapy with a drug called ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for certain early breast cancers that have a low risk of coming back.
Pasadena, CaliforniaAges 18 years+
Hear when a new HER2-negative Breast Cancer trial opens near Los Angeles, CA
We’ll email you when one opens near Los Angeles, CA — at most once a week, no account needed, unsubscribe anytime.
HER2-negative Breast Cancer trials in other cities
Where these studies are running near Los Angeles
Institutions with a site for the recruiting her2-negative breast cancer studies listed above.
- City of Hope · 8 studies
- Cedars-Sinai Medical Center · 7 studies
- Cedars-Sinai Cancer - Tarzana · 6 studies
- Huntington Memorial Hospital · 6 studies
- Tower Cancer Research Foundation · 6 studies
- Torrance Memorial Physician Network · 5 studies
- UC Irvine Health/Chao Family Comprehensive Cancer Center · 5 studies
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care · 5 studies
What taking part in a her2-negative breast cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting her2-negative breast cancer studies in California.
Common questions
- Are there her2-negative breast cancer clinical trials near Los Angeles?
- Yes. We're currently tracking 29 recruiting her2-negative breast cancer studies with a site near Los Angeles, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a her2-negative breast cancer study near Los Angeles?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Los Angeles to take part?
- Not necessarily. These studies have a site near Los Angeles, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a her2-negative breast cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New her2-negative breast cancer studies open near Los Angeles regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.